Implementing the European guidelines for cardiovascular disease prevention in the primary care setting in Cyprus: Lessons learned from a health care services study

Table 3 Proportion of high risk patients on treatment as recommended by the European guidelines^†. Proportion of low risk patients and of unclassified patients on treatment.

*SCORE risk category* *Treatment*	*(1) CVD (n=103)*		*(2) DM2 (n=260)*		*(3) SCORE ≥5% (n=74)*		*(4) SCORE <5% (n=101)*	*(5) Unclassified(n=563)*
	*N (%)*	*Δ(%)*	*N (%)*	*Δ(%)*	*N (%)*	*Δ(%)*	*N (%)*	*N (%)*
ANTIHYPERTENSIVES		3.6		13.1		6.7
• Current	34 (41.0)		86 (40.4)		38 (51.4)		71 (70.3)	382 (67.9)
• Recommended	37 (44.6)		114 (53.5)		43 (58.1))		-	-
LLD		30.2		38.9		47.9
• Current	18 (41.9)		50 (36.8)		27 (38.0)		46 (45.5)	173 (30.7)
• Recommended	31 (72.1)		103 (75.7)		61 (85.9)		-	-
ASPIRIN		53.4		87.7		89.2
• Current	48 (46.6)		32 (12.3)		8 (10.8)		25 (24.8)	13(2.3)
• Recommended	103 (100)		260 (100)		74 (100)		-	-

SCORE risk categories:
(1): Patients with CVD +/- DM2
(2): Patients with DM2 (no CVD)
(3): Patients with neither CVD nor DM2 but with multiple risk factors resulting in a 10 year risk of ≥5% for developing a fatal CVD event; Patients with TC ≥320 mg/dl (≥8 mmol/l) or LDL ≥240 mg/7 dl (≥6 mmlo/l) or BP ≥180/110 mmHg.
(4): Patients with neither CVD nor DM2 but with multiple risk factors resulting in a 10 year risk of <5% for developing a fatal CVD event.
(5): Patients with neither CVD nor DM2 but with missing data on risk factors for score calculation
^†Values are for those patients with available data

ISSN: 1472-6963